Navigation Links
Lightlake Therapeutics Inc. to Apply Company's Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment

LONDON, Jan. 6, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.

Current studies indicate that about 4 out of 10 women have symptoms of PMS, with many women suffering from PMS experiencing a sharp increase in craving for high-sweet and high-fat foods just before menstruation. This behavior is particularly upsetting among those women who are also overweight, which totals about 20 percent of all women of childbearing age. Endorphins, which are natural opioids, are released when sweets and high fat content foods are consumed, and the endorphins can eventually cause a form of food addiction that can be exacerbated by such disorders as PMS. Dr. David Sinclair of the National Institute for Health and Welfare in Finland and the Chief Scientific Officer of Lightlake previous work in the field of addiction has shown that endorphin-reinforced addictions are gradually weakened and removed with medicines called opioid antagonists.

Lightlake Therapeutics Inc. is currently conducting a randomized double blind placebo controlled trial in Helsinki of its patented treatment for extinguishing binge eating using the opioid antagonist, naloxone. In developing a similar treatment for PMS overeating, Lightlake plans to conduct multi-center clinical trials in the near future to address this global healthcare issue.

About Lightlake Therapeutics, Inc.

Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.

Safe Harbor

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Investor Contact:
Mr. Kevin Fickle, President
Tel: +1-925-330-8315

Company Contact:
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-207-034-1943

SOURCE Lightlake Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
2. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
3. Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
4. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
5. Echo Therapeutics Announces $3.6 Million Warrant Exercises
6. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
7. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
8. AuraSense Therapeutics Secures Series B Equity Investment
9. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
10. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
11. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
Post Your Comments:
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):